Athira Pharma shares downgraded to neutral by BTIG

On Wednesday, Athira Pharma (NASDAQ: ATHA) experienced a shift in stock rating as BTIG downgraded the company from Buy to Neutral. The downgrade followed a detailed assessment of the pharmaceutical company's recent clinical trial results for its drug Fosgo. The firm's analyst cited concerns over the drug's development path in a challenging and costly trial environment, where investor skepticism is high.

None of the P values in LIFT-AD looked compelling and the treatment size of both components of the primary GST look smaller than was suggested by the interim look at the data - suggesting treatment effects reversed in the second half of the trial.

Post-trial comments from Athira Pharma's management noted a significantly lower decline in placebo patients among the 200 participants analyzed after the interim assessment.

Despite these challenges, the trial did show a rapid benefit in both the ADAS-Cog11 and ADSC-ADL23 endpoints, which measure cognitive and functional abilities in patients. This benefit appeared to be stronger in patients with more severe symptoms, as indicated by lower scores on the Mini-Mental State Examination (MMSE). However, the effect was noted to be stable rather than increasing over time.

The analyst described the trial as well-conducted with a drug that has a strong pre-clinical foundation. The trial's design aimed to capture the broad effects of the drug.

In other recent news, Athira Pharma's LIFT-AD clinical trial for fosgonimeton, a potential treatment for Alzheimer's disease, did not meet its primary endpoint. Despite this, the treatment showed consistent improvements across biomarkers associated with Alzheimer's disease, particularly in pre-specified subgroups of patients. Fosgonimeton was generally well-tolerated, demonstrating a favorable safety profile.

Athira Pharma also presented new preclinical data at the Alzheimer’s Association International Conference 2024, suggesting that fosgonimeton may reduce key Alzheimer’s disease-related protein pathology and protect neurons from amyloid-β toxicity. These findings support the continued investigation of fosgonimeton's potential impact on Alzheimer's disease pathology.

In other developments, Athira has reached a preliminary settlement in a shareholder derivative lawsuit, which includes the implementation of corporate governance reforms and the coverage of legal fees and expenses. These recent developments reflect Athira Pharma's ongoing commitment to advancing its pipeline of therapeutic candidates. The full analysis of the LIFT-AD results will be reviewed at the upcoming 17th Annual Clinical Trials on Alzheimer's Disease in Madrid, Spain.

InvestingPro Insights

Athira Pharma (NASDAQ: ATHA) has been the subject of investor attention following its clinical trial results and the subsequent downgrade by BTIG. In light of recent events, a closer look at the company's financial health and stock performance provides additional context for interested stakeholders.

InvestingPro Data indicates that Athira Pharma holds a market capitalization of $108.78 million, suggesting a smaller size in the biopharmaceutical industry. The company's Price to Earnings (P/E) ratio stands at -0.96, reflecting its current lack of profitability. Furthermore, with an Operating Income of -$121.4 million over the last twelve months as of Q1 2023, the financials underscore the high costs associated with drug development and the challenges the company faces in reaching profitability.

From the perspective of stock performance, Athira's shares have experienced significant volatility. The 1-week total return on the stock price has seen a drop of 13.98%, while the 3-month return has shown a strong increase of 15.98%. This volatility is indicative of the uncertainties and rapid shifts in investor sentiment that can be common in the pharmaceutical sector, especially for companies in the critical stages of drug development trials.

InvestingPro Tips reveal that Athira Pharma does not pay a dividend to shareholders, which is typical for companies focused on reinvesting earnings into research and development. Additionally, analysts do not anticipate the company will be profitable this year, aligning with the P/E ratio data.

For those looking to delve deeper into Athira Pharma's financials and stock performance, InvestingPro offers a wealth of additional tips. Currently, there are 10 more InvestingPro Tips available that provide insights into the company's financial position and market performance. These tips can be especially useful for investors seeking to understand the intricacies of Athira's operational and financial strategies in the context of its recent clinical trial outcomes and stock rating downgrade.

For further details and to explore all the tips, visit InvestingPro at https://www.investing.com/pro/ATHA.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.